Figure 1.

Development and characterization of post-TMZ GBM6 PDX. (A) Illustration of the process for creating post-TMZ, MMR-deficient PDX. Parental GBM6 cells were engrafted intracranially in nod-scid-gamma (NGS) mice, then treated with 3 cycles of TMZ. When tumors recurred and mice succumbed, tumor tissue was implanted into the flank of a new mouse. When flank tumors grew to sufficient size, they were harvested and processed for subsequent in vitro and in vivo therapy testing. (B) MMR protein and (C) MGMT protein expressions in derivative GBM6 PDX flank tissue from 4 mice. Each PDX received 3 cycles of TMZ as an intracranial tumor. MGMT = O-6-methylguanine-DNA methyltransferase; MMR = mismatch repair; PDX = patient-derived xenograft; TMZ = temozolomide